Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Antiemetic

Therapeutic area intelligence for Antiemetic with 17 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 17
Catalysts: 0
Companies: 2

Companies

Orbit Pharma Limited →

Assets

Domperidone →

Fosaprepitant Dimeglumine →

Recent signals(17)

RegulatoryAugust 3, 2026

FDA Approval Process Update for Ondansetron Hydrochloride Preservative Free

The FDA has updated the submission status for ANDA078945 for Ondansetron Hydrochloride Preservative Free to Approved (AP).

RegulatoryAugust 2, 2026

Fresenius Kabi's Ondansetron Hydrochloride Preservative Free Receives AP Status

Fresenius Kabi USA's application for Ondansetron Hydrochloride Preservative Free has received an Abbreviated Approval (AP) status from the FDA.

RegulatoryAugust 1, 2026

Fresenius Kabi's Ondansetron Hydrochloride ANDA076974 Receives AP Status

Fresenius Kabi USA has received an Abbreviated New Drug Application (ANDA) approval status for Ondansetron Hydrochloride.

RegulatoryAugust 1, 2026

FDA Grants AP Status for Fosaprepitant Dimeglumine ANDA203939

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Fosaprepitant Dimeglumine submitted by Caplin.

RegulatoryAugust 1, 2026

Lupin's Fosaprepitant Dimeglumine Supplement Receives FDA AP Status

The FDA has granted an Abbreviated Approval (AP) status for Lupin's supplemental application for Fosaprepitant Dimeglumine.

RegulatoryJuly 27, 2026

FDA Approves Ondansetron Hydrochloride Preservative Free Supplement

The FDA has approved the supplement application for Ondansetron Hydrochloride Preservative Free by ONESOURCE SPECIALTY.

RegulatoryJuly 26, 2026

FDA Approval Status Update for Ondansetron Hydrochloride Supplement

The FDA has granted an approval status (AP) for the Ondansetron Hydrochloride supplement submitted by Onesource Specialty.

RegulatoryJuly 22, 2026

Domperidone Updated with New Contraindication for Phaeochromocytoma Patients

Domperidone products now include a contraindication for patients with confirmed or suspected phaeochromocytoma due to severe hypertension risk.

RegulatoryJuly 11, 2026

FDA Grants AP Status for Ondansetron Hydrochloride Preservative Free

The FDA has granted approval status (AP) for the ANDA078945 application for Ondansetron Hydrochloride Preservative Free by Avet Lifesciences.

RegulatoryJuly 11, 2026

Lupin's ANDA for Fosaprepitant Dimeglumine Receives AP Status from FDA

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Lupin's Fosaprepitant Dimeglumine.

RegulatoryJuly 4, 2026

FDA Grants AP Status for Ondansetron Hydrochloride Preservative Free

The FDA has granted approval status (AP) for Ondansetron Hydrochloride Preservative Free submitted by ONESOURCE SPECIALTY.

StrategyJuly 4, 2026

FDA Grants Approval for Ondansetron Hydrochloride ANDA078257

The FDA has granted approval for ANDA078257, a generic formulation of Ondansetron Hydrochloride by ONESOURCE SPECIALTY.

RegulatoryJune 30, 2026

FDA Accepts NDA for NAVITRUX by AVYXA HOLDINGS

The FDA has accepted the New Drug Application (NDA) for NAVITRUX, an antiemetic containing fosaprepitant.

RegulatoryJune 23, 2026

FDA Review Status Update for Aprepitant NDA218754 by Azurity

The FDA has received a new drug application (NDA218754) for Aprepitant from Azurity, currently under standard review.

RegulatoryJune 21, 2026

FDA Grants AP Status for Fosaprepitant Dimeglumine ANDA212143

The FDA has granted approval status (AP) for the ANDA212143 application for Fosaprepitant Dimeglumine submitted by Chia Tai Tianqing.

RegulatoryJune 19, 2026

Orbit Pharma recalls Cyclizine Lactate due to GMP deficiencies

Orbit Pharma Limited is recalling a batch of Cyclizine Lactate 50 mg/ml Solution for injection due to GMP deficiencies.

RegulatoryJune 6, 2026

FDA Submission Update for Ondansetron Hydrochloride (ANDA078127)

The FDA has received a supplemental application (ANDA078127) for Ondansetron Hydrochloride from PHARM ASSOC.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.